Triple-negative breast cancer (TNBC) lacks hormonal and HER2 targets, making it notoriously difficult to treat. This review examines how mRNA therapeutics are emerging as a powerful new approach, covering three main strategies: personalized cancer vaccines targeting tumor-specific antigens like MAGE-A3 and neoantigens from TP53/BRCA mutations; mRNA-engineered CAR-T and TCR-T immune cells directed at surface targets including ROR1 and Trop-2; and mRNA-delivered immunomodulators such as IL-12 and OX40L to reprogram the suppressive tumor environment. Advanced lipid nanoparticles are central to delivering mRNA safely and effectively. The authors argue these converging technologies could overcome the immune evasion and heterogeneity that currently limit checkpoint inhibitor therapy in TNBC.